Soligenix's HyBryte Clinical Data Published in Peer-Reviewed Journal, Supporting Potential as First-Line CTCL Treatment

The publication of comprehensive clinical trial data for HyBryte in a peer-reviewed journal represents a significant milestone for Soligenix's development of this novel photodynamic therapy for cutaneous T-cell lymphoma. The article in Expert Opinion on Investigational Drugs highlights the therapy's safety profile, non-mutagenic mechanism, and demonstrated efficacy across multiple studies, providing scientific validation as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026. This publication supports HyBryte's potential as a first-line treatment option for CTCL patients, addressing an unmet medical need in this rare disease area.

The clinical data summary emphasizes HyBryte's unique mechanism of action as a synthetic hypericin sodium formulation that utilizes safe visible light rather than ultraviolet radiation, which distinguishes it from other photodynamic therapies. This non-mutagenic approach is particularly important for CTCL patients who require long-term treatment and face increased cancer risks with traditional therapies. The published findings consolidate results from multiple studies, demonstrating consistent efficacy while maintaining a favorable safety profile that could position HyBryte as a preferred treatment option if regulatory approvals are obtained following successful completion of the second Phase 3 study.

Soligenix's advancement of HyBryte through the clinical development pathway reflects the company's focus on rare diseases with significant unmet medical needs. The publication timing coincides with the company's progress toward potential commercialization worldwide, with regulatory submissions anticipated upon successful trial completion. The peer-reviewed validation provided by Expert Opinion on Investigational Drugs adds credibility to the therapy's development program and may influence both regulatory considerations and clinical adoption patterns. This scientific endorsement comes at a critical juncture as the company prepares for the interim analysis of its Phase 3 trial, which could provide additional data to support the therapy's efficacy and safety claims.

The broader implications of this development extend beyond HyBryte's specific application for CTCL, as Soligenix is also investigating synthetic hypericin for other conditions including psoriasis through its SGX302 program. The company's research pipeline includes additional therapeutic candidates such as dusquetide for inflammatory diseases and vaccine programs targeting various infectious diseases, supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases. The full terms of use and disclaimers applicable to this content are available on the InvestorBrandNetwork website, while the latest news and updates relating to Soligenix are accessible in the company's newsroom. The publication of this clinical data summary represents an important step in establishing HyBryte's scientific foundation as Soligenix continues to advance its development programs toward potential regulatory approval and commercialization.